RSV in babies
24th February 2022
What is RSV in babies? Respiratory Syncytial Virus, commonly referred to as RSV, is a respiratory virus that causes cold-like symptoms in the typical healthy adult, which can last on
What is RSV in babies? Respiratory Syncytial Virus, commonly referred to as RSV, is a respiratory virus that causes cold-like symptoms in the typical healthy adult, which can last on
Poolbeg Pharma plc (LON:POLB) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an agreement with OneThree Biotech, Inc. a biology-driven artificial intelligence company, to identify new drug
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
Infectious disease company Poolbeg Pharma has secured a licence to develop an immunotherapy treatment to target respiratory virus infections which could include Covid-19. The dual antiviral prophylactic and therapeutic candidate, which
Poolbeg Pharma plc (LON:POLB) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, confirmed today that it has signed the licence to AnaBio Technologies’ microencapsulation and nanoencapsulation technologies to develop
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
The company has secured an exclusive license to a dual antiviral prophylactic and therapeutic candidate, which is currently at a late-pre-clinical development stage. The immunotherapy candidate is able to target
A Cork-based firm, led by Dr Sinéad Bleiel, is trying to adapt its encapsulation technology to deliver vaccines in partnership with Poolbeg Pharm The biggest challenge for any medical research scientist is to translate
Poolbeg Pharma’s Jeremy Skillington discusses the in-licenced novel, first-in-class RNA-based immunotherapy for respiratory virus infections developed at the University of Warwick and the ultimate plan for the deal in this exclusive interview with DirectorsTalk.
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
